Cargando…
Sequential implementation of DSC-MR perfusion and dynamic [(18)F]FET PET allows efficient differentiation of glioma progression from treatment-related changes
PURPOSE: Perfusion-weighted MRI (PWI) and O-(2-[(18)F]fluoroethyl-)-l-tyrosine ([(18)F]FET) PET are both applied to discriminate tumor progression (TP) from treatment-related changes (TRC) in patients with suspected recurrent glioma. While the combination of both methods has been reported to improve...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113145/ https://www.ncbi.nlm.nih.gov/pubmed/33241456 http://dx.doi.org/10.1007/s00259-020-05114-0 |
_version_ | 1783690799479783424 |
---|---|
author | Steidl, Eike Langen, Karl-Josef Hmeidan, Sarah Abu Polomac, Nenad Filss, Christian P. Galldiks, Norbert Lohmann, Philipp Keil, Fee Filipski, Katharina Mottaghy, Felix M. Shah, Nadim Jon Steinbach, Joachim P. Hattingen, Elke Maurer, Gabriele D. |
author_facet | Steidl, Eike Langen, Karl-Josef Hmeidan, Sarah Abu Polomac, Nenad Filss, Christian P. Galldiks, Norbert Lohmann, Philipp Keil, Fee Filipski, Katharina Mottaghy, Felix M. Shah, Nadim Jon Steinbach, Joachim P. Hattingen, Elke Maurer, Gabriele D. |
author_sort | Steidl, Eike |
collection | PubMed |
description | PURPOSE: Perfusion-weighted MRI (PWI) and O-(2-[(18)F]fluoroethyl-)-l-tyrosine ([(18)F]FET) PET are both applied to discriminate tumor progression (TP) from treatment-related changes (TRC) in patients with suspected recurrent glioma. While the combination of both methods has been reported to improve the diagnostic accuracy, the performance of a sequential implementation has not been further investigated. Therefore, we retrospectively analyzed the diagnostic value of consecutive PWI and [(18)F]FET PET. METHODS: We evaluated 104 patients with WHO grade II–IV glioma and suspected TP on conventional MRI using PWI and dynamic [(18)F]FET PET. Leakage corrected maximum relative cerebral blood volumes (rCBV(max)) were obtained from dynamic susceptibility contrast PWI. Furthermore, we calculated static (i.e., maximum tumor to brain ratios; TBR(max)) and dynamic [(18)F]FET PET parameters (i.e., Slope). Definitive diagnoses were based on histopathology (n = 42) or clinico-radiological follow-up (n = 62). The diagnostic performance of PWI and [(18)F]FET PET parameters to differentiate TP from TRC was evaluated by analyzing receiver operating characteristic and area under the curve (AUC). RESULTS: Across all patients, the differentiation of TP from TRC using rCBV(max) or [(18)F]FET PET parameters was moderate (AUC = 0.69–0.75; p < 0.01). A rCBV(max) cutoff > 2.85 had a positive predictive value for TP of 100%, enabling a correct TP diagnosis in 44 patients. In the remaining 60 patients, combined static and dynamic [(18)F]FET PET parameters (TBR(max), Slope) correctly discriminated TP and TRC in a significant 78% of patients, increasing the overall accuracy to 87%. A subgroup analysis of isocitrate dehydrogenase (IDH) mutant tumors indicated a superior performance of PWI to [(18)F]FET PET (AUC = 0.8/< 0.62, p < 0.01/≥ 0.3). CONCLUSION: While marked hyperperfusion on PWI indicated TP, [(18)F]FET PET proved beneficial to discriminate TP from TRC when PWI remained inconclusive. Thus, our results highlight the clinical value of sequential use of PWI and [(18)F]FET PET, allowing an economical use of diagnostic methods. The impact of an IDH mutation needs further investigation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-020-05114-0. |
format | Online Article Text |
id | pubmed-8113145 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-81131452021-05-12 Sequential implementation of DSC-MR perfusion and dynamic [(18)F]FET PET allows efficient differentiation of glioma progression from treatment-related changes Steidl, Eike Langen, Karl-Josef Hmeidan, Sarah Abu Polomac, Nenad Filss, Christian P. Galldiks, Norbert Lohmann, Philipp Keil, Fee Filipski, Katharina Mottaghy, Felix M. Shah, Nadim Jon Steinbach, Joachim P. Hattingen, Elke Maurer, Gabriele D. Eur J Nucl Med Mol Imaging Original Article PURPOSE: Perfusion-weighted MRI (PWI) and O-(2-[(18)F]fluoroethyl-)-l-tyrosine ([(18)F]FET) PET are both applied to discriminate tumor progression (TP) from treatment-related changes (TRC) in patients with suspected recurrent glioma. While the combination of both methods has been reported to improve the diagnostic accuracy, the performance of a sequential implementation has not been further investigated. Therefore, we retrospectively analyzed the diagnostic value of consecutive PWI and [(18)F]FET PET. METHODS: We evaluated 104 patients with WHO grade II–IV glioma and suspected TP on conventional MRI using PWI and dynamic [(18)F]FET PET. Leakage corrected maximum relative cerebral blood volumes (rCBV(max)) were obtained from dynamic susceptibility contrast PWI. Furthermore, we calculated static (i.e., maximum tumor to brain ratios; TBR(max)) and dynamic [(18)F]FET PET parameters (i.e., Slope). Definitive diagnoses were based on histopathology (n = 42) or clinico-radiological follow-up (n = 62). The diagnostic performance of PWI and [(18)F]FET PET parameters to differentiate TP from TRC was evaluated by analyzing receiver operating characteristic and area under the curve (AUC). RESULTS: Across all patients, the differentiation of TP from TRC using rCBV(max) or [(18)F]FET PET parameters was moderate (AUC = 0.69–0.75; p < 0.01). A rCBV(max) cutoff > 2.85 had a positive predictive value for TP of 100%, enabling a correct TP diagnosis in 44 patients. In the remaining 60 patients, combined static and dynamic [(18)F]FET PET parameters (TBR(max), Slope) correctly discriminated TP and TRC in a significant 78% of patients, increasing the overall accuracy to 87%. A subgroup analysis of isocitrate dehydrogenase (IDH) mutant tumors indicated a superior performance of PWI to [(18)F]FET PET (AUC = 0.8/< 0.62, p < 0.01/≥ 0.3). CONCLUSION: While marked hyperperfusion on PWI indicated TP, [(18)F]FET PET proved beneficial to discriminate TP from TRC when PWI remained inconclusive. Thus, our results highlight the clinical value of sequential use of PWI and [(18)F]FET PET, allowing an economical use of diagnostic methods. The impact of an IDH mutation needs further investigation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-020-05114-0. Springer Berlin Heidelberg 2020-11-26 2021 /pmc/articles/PMC8113145/ /pubmed/33241456 http://dx.doi.org/10.1007/s00259-020-05114-0 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Steidl, Eike Langen, Karl-Josef Hmeidan, Sarah Abu Polomac, Nenad Filss, Christian P. Galldiks, Norbert Lohmann, Philipp Keil, Fee Filipski, Katharina Mottaghy, Felix M. Shah, Nadim Jon Steinbach, Joachim P. Hattingen, Elke Maurer, Gabriele D. Sequential implementation of DSC-MR perfusion and dynamic [(18)F]FET PET allows efficient differentiation of glioma progression from treatment-related changes |
title | Sequential implementation of DSC-MR perfusion and dynamic [(18)F]FET PET allows efficient differentiation of glioma progression from treatment-related changes |
title_full | Sequential implementation of DSC-MR perfusion and dynamic [(18)F]FET PET allows efficient differentiation of glioma progression from treatment-related changes |
title_fullStr | Sequential implementation of DSC-MR perfusion and dynamic [(18)F]FET PET allows efficient differentiation of glioma progression from treatment-related changes |
title_full_unstemmed | Sequential implementation of DSC-MR perfusion and dynamic [(18)F]FET PET allows efficient differentiation of glioma progression from treatment-related changes |
title_short | Sequential implementation of DSC-MR perfusion and dynamic [(18)F]FET PET allows efficient differentiation of glioma progression from treatment-related changes |
title_sort | sequential implementation of dsc-mr perfusion and dynamic [(18)f]fet pet allows efficient differentiation of glioma progression from treatment-related changes |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113145/ https://www.ncbi.nlm.nih.gov/pubmed/33241456 http://dx.doi.org/10.1007/s00259-020-05114-0 |
work_keys_str_mv | AT steidleike sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges AT langenkarljosef sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges AT hmeidansarahabu sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges AT polomacnenad sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges AT filsschristianp sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges AT galldiksnorbert sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges AT lohmannphilipp sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges AT keilfee sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges AT filipskikatharina sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges AT mottaghyfelixm sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges AT shahnadimjon sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges AT steinbachjoachimp sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges AT hattingenelke sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges AT maurergabrieled sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges |